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Background: Due to the low incidence of thymoma, there is little 
high-quality evidence on the clinical management of thymoma. Much 
of the evidence consists of small retrospective case series. As a result, 
in 2006, a working group of the provincial Lung Disease Site Group 
undertook a formal consensus process to develop a guideline for the 
management of malignant thymoma through Cancer Care Ontario’s 
Program in Evidence-based Care (PEBC).
Methods: The consensus process followed a traditional evidence-based 
guideline development process, beginning with a systematic search of 
the literature and a review of evidence. Members of the DSG reviewed 
the studies available from 1996 onwards and and met in two teleconfer-
ences to draft preliminary recommendations. A modiﬁed-Delphi formal 
consensus process was then undertaken. The draft recommendations 
were distributed as a survey to a sample of relevant clinicians from 
across Canada (n=68) for two rounds of response. Round one entailed 
respondents reviewing a brief evidence summary, with instructions 
to rate their degree of agreement or disagreement (scale 1 to 7, 1 = 
strongly agree, 7 = strongly disagree) for each of the 38 thymoma man-
agement recommendations proposed by the Lung DSG working group. 
Results: In Round One, responses were received from 32/68 (47%) of 
individuals surveyed. Of the 38 recommendations, 9 were identiﬁed 
as having signiﬁcant variability in agreement amongst reviewers. In 
Round Two, a statistical and graphical representation of results from 
Round One were distributed, and respondents were asked to re-rate 
their agreement with recommendations, in consideration of the group 
responses. For some items respondents articulated possible changes 
to the recommendations in their written feedback. These were incor-
porated in the Round Two questionnaire as ‘options’, and respondents 
were asked to identify their agreement with the original and with the 
modiﬁed second recommendation. 
Conclusion: The results from Round Two are pending; the working 
group will reconvene via teleconference to conﬁrm that issues of prior 
disagreement have been appropriately addressed, and/or made explicit 
in the ﬁnal report. Final consensus guideline recommendations will be 
presented.
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Background: The widespread use of asbestos during the 20th century 
has produced a legacy of ill-health, death and contamination which will 
endure well into the current century. Epidemics of asbestos illness have 
been reported in industrialized countries for many years; now, data 
are being collated which document an escalation of these diseases in 
developing countries such as Brazil, Thailand and Egypt.
Asbestos manufacturing began in Egypt more than 50 years ago. By 
2004, there were 14 asbestos factories employing thousands of work-
ers. Asbestos is imported from Russia and Canada and is used for the 
manufacture of asbestos-cement pipes, rooﬁng and wall materials, 
valves, joints, sealants, clothing, cords, strings, clutches, brake linings 
and pads; crocidolite and amosite were used in pipes and corrugated 
sheets until fairly recently. The working conditions in these factories 
were poor and included occupational exposure to various asbestos 
types on a daily basis.
Methods and Results: In the ﬁrst 5 years of the 3rd millennium 
(2000-2004), 832 cases of mesothelioma were diagnosed at NCI, and 
Abbassia Chest Hospital, Cairo. Both hospitals drain and serve most 
of the high risk population living in the neighborhoods of the oldest 
asbestos production plants. Median age was 53 (19-90) years. Females 
represented 39.2% and young adults ≤ 40 years represented 19.1%. 
Residential exposure was evidenced in 64.7% of cases (Shobra El-
khema, 35.6%, El-Maasara and surrounding area 23.6%, El Zytoon 
5.2%, and others 0.5%). Twenty ﬁve percent came from other Cairo 
areas and 9.8% from other governorates. The NCI hospital based-reg-
istry showed an increase in the relative frequency of MPM from 0.47% 
in 2001, to 1.4% in 2004.
In a trial to ﬁnd a relation between residency and asbestos exposure, 
a ﬁeld study was done to investigate the residential areas surrounding 
the oldest factory in El-Maasara, Cairo. Heaps of asbestos wastes with 
breaks of cement pipes and sheets were visualized outside the fence 
of the factory, improperly disposed off. Repeated airborne asbestos 
samples were collected using National Institute for Occupational Safety 
and Health (NIOSH) method No 7400. Results showed the presence of 
asbestos ﬁbers in those residential areas in counts ranging from 0.002 
f/cc, 7 kilometers from the factory, to levels beyond permissible expo-
sure limits and excursion limit (3.02 f/cc) few meters from the factory. 
Although the Egyptian Minister of Foreign Trade and Industry prohib-
ited the import and manufacture of all types of asbestos and asbestos 
materials in 2006, it is believed that chrysotile is still being used in the 
manufacture of asbestos-cement materials. 
The NCI, Cairo recommendations include periodic monitoring of the 
environment inside and outside the factories for permissible exposure 
limits (PEL), increasing awareness of the public regarding the risk of 
asbestos exposure, education and protection of Egyptian asbestos work-
ers, follow up and if possible periodical medical checks for population 
at risk of occupational and/or residential exposure.
Conclusion: There is a clear need for stronger legislative measures to 
eliminate asbestos entirely in order to combat the coming epidemic of 
mesothelioma in Egypt. 
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Background: Malignant pleural mesothelioma (MPM) is an uncom-
mon but extremely aggressive tumor of the pleura which has been 
closely linked to asbestos exposure. Over the last decade, a variety of 
receptor tyrosine kinases have been identiﬁed to play a central role in 
various aspects of tumorigenesis. One of these, EGFR, is overexpressed 
in the majority of MPMs and appears to play an important role in the 
pathogenesis of the disease. The aim of the present study was to inves-
tigate the potential value of tissue and serum EGFR for the diagnosis of 
MPM and to assess its predictive value in relation to survival.
Methods: We prospectively investigated 90 cases of pathologically-
proven MPM presenting at NCI Cairo. All cases were conﬁrmed using 
immunohistochemical markers. Epithelioid cases were positive to 
calretinine, mesothelioma antigen, keratin 5/6 and negative to epithelial 
membrane antigen and/or cytokeratin and/or CEA. Sarcomatoid cases 
were diagnosed by being positive for mesothelioma antigen and nega-
tive for vimentin. Out of the 90 MPM cases, 71 and 40 had undergone 
determination of the EGFR on the tissue and serum respectively. 
Results. Major clinical characteristics in MPM patients were: a median 
age 46, range (26-77) years, a M/F ratio 1.7:1, 28.2% of the cases were 
early stage, 35% had a performance status 2 and 70% gave a history 
of asbestos exposure. 57.8% of the cases were epithelioid, 23.3% were 
mixed, and 7.8% were sarcomatoid. Among all treated patients, the 
overall response rate (RR) was 32.8%. After a median follow up of 29 
months, the median overall survival (MOS) was 10 months. Using a 
cut-off point of 2.5 ng/ml for EGFR in serum (corresponding to the me-
dian of marker concentration in MPM), it was found to be signiﬁcantly 
associated with advanced stage. Using a normal cut-off value >0.23 
ng/ml, a borderline signiﬁcance with response to treatment was found. 
EGFR overexpression in tissues and high serum levels were not associ-
ated with unfavorable survival outcome. We have previously studied 
the correlation between EGFR overexpression EGFR in tissue samples 
in a subset group of this series for a shorter follow-up period (median 
follow-up), and we reported a highly signiﬁcant relation between 
EGFR expression and the OS rate. However, on a prospective, longer 
follow-up of these patients this signiﬁcant association was not revealed. 
Conclusions: 1- A high pretreatment levels of serum EGFR are associ-
ated with poor prognosis and unfavorable response to treatment but not 
with reduced OS. 2- Although increased EGFR expression in tissues 
is signiﬁcantly associated with OS rates in a short follow-up period, 
this signiﬁcant relation is not revealed on a long term follow-up. The 
explanation of this needs detailed genetic studies to determine the 
exact genetic defects (mutations or SNP) that might contribute to poor 
survival rather than protein overexpression.
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Background: Primary mass lesions arising from the mediastinum are 
uncommon. Their origins vary and they have multiple manifestations. 
Studies reporting these tumors are few and tumor registries provide an 
objective collection method to elucidate their characteristics.
Methods: A comprehensive review of all mediastinal lesions in the 
tumor registry of the Philippine Heart Center was undertaken and ana-
lyzed, which covered a 5-year period (2001-2006). 
Results: Seventy-nine mediastinal mass lesions from patients who 
underwent thoracotomy at our center were analyzed during the review 
period. Fifty-two (65.8%) were benign and the rest were malignant. 
Thymoma, 24 (30.4%) was the most common tumor in the series and 
was noted more on the female population. For the pediatric age group, 
the most common lesion was teratoma, 5 (55.6%). Non-Hodgkins 
lymphoma, 10 (12.7%) was the most common malignancy encountered 
in the entire population. Other pathologies encountered were mature 
teratoma, thymic carcinoma, Hodgkins lymphoma, thymic cysts, 
thymic carcinoid, teratocarcinoma, aberrant thyroid tissue, neurogenic 
tumors, vascular malformations, small cell carcinoma, lipoma, spindle 
cell tumor, bronchogenic cyst, and non-speciﬁc inﬂammatory lesion. 
Seventy-ﬁve (94.9%) of these tumors are located in the anterior medi-
astinum, 3 (3.8%) are in the posterior compartment, and only 1 (1.3%) 
arose from the superior portion. Immunohistochemical staining was 
done in most of the malignant lesions which included cytokeratin, CD 
3, CD 20, CD 15, CD 30, and LCA. The mean age was 39 (9 months 
- 87 years). There were 34 males (43%) and 45 females (57%). Nine 
(11.4%) belong to the pediatric age group (18 years old and below) and 
70 belong to the adult age group. Majority of these patients presented 
with dyspnea and cough. A few had incidental ﬁnding on routine radio-
logic examination.
Conclusion: Majority of the masses in the mediastinum arose from 
its anterior compartment and thymic lesions were mostly encountered. 
Thymomas constituted the majority of lesions among adults while 
teratomas predominate in the pediatric age group. Lymphomas were 
the most common malignancies in both populations. These differ-
ences should be considered when evaluating patients with mediastinal 
lesions. 
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Background: Promising results, even debated and not yet uniformly 
replicated, with trimodality treatment combining extra pleural pneumo-
nectomy (EPP), chemotherapy, and radiotherapy have been obtained in 
the management of malignant pleural mesothelioma (MPM). Neverthe-
less several prognostic parameters have to be taken into account before 
this aggressive management. Among them the histological subtype of 
the disease has an inﬂuence on the patient’s outcome with pejorative 
prognosis for non epithelial type. The aim of the present study was to 
retrospectively investigate the accuracy of thoracoscopy pleural biopsy 
for the diagnosis and histological subtype of MPM.
Methods: The histological reports of all consecutive patients undergo-
ing an ‘intention-to-treat’ surgery, i.e. EPP, pleurectomy (P), pleurec-
tomy/decortication (P/D) from three institutions as well as the initial 
pathological diagnosis obtained by thoracoscopy were reviewed and 
compared after institutional review board approval. All cases of MPM 
were conﬁrmed by a panel of pathologists (the “Mesopath” panel in 
France).
